These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24090875)

  • 1. Effects of ageing, prolonged estrogen deficiency and zoledronate on bone tissue mineral distribution.
    Brennan MA; Gleeson JP; O'Brien FJ; McNamara LM
    J Mech Behav Biomed Mater; 2014 Jan; 29():161-70. PubMed ID: 24090875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of estrogen deficiency and bisphosphonate treatment on tissue mineralisation and stiffness in an ovine model of osteoporosis.
    Brennan O; Kennedy OD; Lee TC; Rackard SM; O'Brien FJ; McNamara LM
    J Biomech; 2011 Feb; 44(3):386-90. PubMed ID: 21093863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of estrogen deficiency and bisphosphonate therapy on osteocyte viability and microdamage accumulation in an ovine model of osteoporosis.
    Brennan O; Kennedy OD; Lee TC; Rackard SM; O'Brien FJ
    J Orthop Res; 2011 Mar; 29(3):419-24. PubMed ID: 20886644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
    Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
    J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site specific increase in heterogeneity of trabecular bone tissue mineral during oestrogen deficiency.
    Brennan MA; Gleeson JP; Browne M; O'Brien FJ; Thurner PJ; McNamara LM
    Eur Cell Mater; 2011 May; 21():396-406. PubMed ID: 21574136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats.
    Hornby SB; Evans GP; Hornby SL; Pataki A; Glatt M; Green JR
    Calcif Tissue Int; 2003 Apr; 72(4):519-27. PubMed ID: 12574877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort.
    Misof BM; Roschger P; Gabriel D; Paschalis EP; Eriksen EF; Recker RR; Gasser JA; Klaushofer K
    J Bone Miner Res; 2013 Mar; 28(3):442-8. PubMed ID: 23044788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study.
    Fratzl-Zelman N; Roschger P; Fisher JE; Duong LT; Klaushofer K
    Calcif Tissue Int; 2013 Mar; 92(3):261-9. PubMed ID: 23179105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis.
    Little DG; Smith NC; Williams PR; Briody JN; Bilston LE; Smith EJ; Gardiner EM; Cowell CT
    J Bone Miner Res; 2003 Jul; 18(7):1300-7. PubMed ID: 12854841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength.
    Yao W; Cheng Z; Koester KJ; Ager JW; Balooch M; Pham A; Chefo S; Busse C; Ritchie RO; Lane NE
    Bone; 2007 Nov; 41(5):804-12. PubMed ID: 17825637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats.
    Li GW; Xu Z; Chang SX; Zhou L; Wang XY; Nian H; Shi X
    Endocrinology; 2014 Dec; 155(12):4731-8. PubMed ID: 25243855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
    Zoehrer R; Roschger P; Paschalis EP; Hofstaetter JG; Durchschlag E; Fratzl P; Phipps R; Klaushofer K
    J Bone Miner Res; 2006 Jul; 21(7):1106-12. PubMed ID: 16813531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling.
    McDonald MM; Dulai S; Godfrey C; Amanat N; Sztynda T; Little DG
    Bone; 2008 Oct; 43(4):653-62. PubMed ID: 18582604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
    Uyar Y; Baytur Y; Inceboz U; Demir BC; Gumuser G; Ozbilgin K
    Maturitas; 2009 Jul; 63(3):261-7. PubMed ID: 19386450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of minodronic acid and alendronate on bone remodeling, microdamage accumulation, degree of mineralization and bone mechanical properties in ovariectomized cynomolgus monkeys.
    Yamagami Y; Mashiba T; Iwata K; Tanaka M; Nozaki K; Yamamoto T
    Bone; 2013 May; 54(1):1-7. PubMed ID: 23356990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates do not alter the rate of secondary mineralization.
    Fuchs RK; Faillace ME; Allen MR; Phipps RJ; Miller LM; Burr DB
    Bone; 2011 Oct; 49(4):701-5. PubMed ID: 21619951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralization density distribution of postmenopausal osteoporotic bone is restored to normal after long-term alendronate treatment: qBEI and sSAXS data from the fracture intervention trial long-term extension (FLEX).
    Roschger P; Lombardi A; Misof BM; Maier G; Fratzl-Zelman N; Fratzl P; Klaushofer K
    J Bone Miner Res; 2010 Jan; 25(1):48-55. PubMed ID: 19580465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid improves bone mineral density, reduces bone turnover and improves skeletal architecture over 2 years of treatment in children with secondary osteoporosis.
    Simm PJ; Johannesen J; Briody J; McQuade M; Hsu B; Bridge C; Little DG; Cowell CT; Munns CF
    Bone; 2011 Nov; 49(5):939-43. PubMed ID: 21820091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid.
    Gamsjaeger S; Buchinger B; Zwettler E; Recker R; Black D; Gasser JA; Eriksen EF; Klaushofer K; Paschalis EP
    J Bone Miner Res; 2011 Jan; 26(1):12-8. PubMed ID: 20645415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.